 |
|
Reoperative Parathyroid Surgery in the Era of Sestamibi Scanning and Intraoperative Parathyroid Hormone Monitoring
Geoffrey B. Thompson, MD;
Clive S. Grant, MD;
Nancy D. Perrier, MD;
Richard Harman, MD;
Stephen F. Hodgson, MD;
Duane Ilstrup, MS;
Jon A. van Heerden, MB
Arch Surg. 1999;134:699-705.
Hypothesis Results of reoperative parathyroid surgery (RPS) have improved with the advent of sestamibi parathyroid subtraction scanning and intraoperative parathyroid hormone (IOPTH) monitoring.
Design Retrospective review of patient histories, preoperative localization studies, operative data, including IOPTH monitoring, and outcomes for patients undergoing recent RPS at a single institution. Follow-up was complete (mean, 20 months).
Setting Tertiary care referral center.
Patients All patients undergoing RPS for benign persistent or recurrent primary hyperparathyroidism during the period 1989 to 1997.
Main Outcome Measures Overall cure rate and operative morbidity from RPS; sensitivity and accuracy of preoperative localization studies; and prediction of cure from IOPTH monitoring.
Results The study group included 124 patients (87 women and 37 men). Hypercalcemia was corrected in 109 patients (88%). Permanent recurrent laryngeal nerve injury occurred in 0.8% and permanent hypoparathyroidism in 13% of patients. Test sensitivities and accuracies, respectively, were as follows: ultrasound with biopsy, 90% and 82%; sestamibi parathyroid subtraction scanning, 82% and 67%; and ultrasound alone, 75% and 65%. Level of IOPTH was predictive of cure in all patients with a 70% or greater fall from baseline at 20 minutes after excision. Persistent multigland disease was the major cause for reoperative failure (73%).
Conclusions Neither cure rates nor operative morbidity have changed appreciably over the past 2 decades, despite the introduction of sestamibi parathyroid subtraction scanning and IOPTH monitoring. Multigland disease continues to represent the principal cause of failure in RPS despite the routine use of preoperative localization studies. Thus far, increasing the stringency of IOPTH monitoring from a 50% to 70% decline from baseline levels has been predictive of cure, even in multigland disease. Most missed abnormal glands reside in normal anatomic locations, and the need for multiple operations, not just the reoperation, results in the increased morbidity seen with RPS.
From the Division of Gastroenterologic and General Surgery (Drs Thompson, Grant, Perrier, and Harman, and Mr van Heerden), Division of Endocrinology, Metabolism, Nutrition, and Internal Medicine (Dr Hodgson), and the Section of Biostatistics (Mr Ilstrup), Mayo Clinic and Mayo Foundation, Rochester, Minn.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Percutaneous Parathyroid Ethanol Ablation in Patients with Multiple Endocrine Neoplasia Type 1
Veldman et al.
Am. J. Roentgenol. 2008;191:1740-1744.
ABSTRACT
| FULL TEXT
Parathyroid Hormone Venous Sampling Before Reoperative Surgery in Renal Hyperparathyroidism: Comparison With Noninvasive Localization Procedures and Review of the Literature
Seehofer et al.
Arch Surg 2004;139:1331-1338.
ABSTRACT
| FULL TEXT
Rapid Intraoperative Immunoassay of Parathyroid Hormone and Other Hormones: A New Paradigm for Point-of-Care Testing
Sokoll et al.
Clin. Chem. 2004;50:1126-1135.
ABSTRACT
| FULL TEXT
Intraoperative Monitoring of Parathyroid Hormone with a Rapid Automated Assay that is Commercially Available
Kao et al.
Annals of Clinical & Laboratory Science 2002;32:244-251.
ABSTRACT
| FULL TEXT
Pitfalls of Intraoperative Quick Parathyroid Hormone Monitoring and Gamma Probe Localization in Surgery for Primary Hyperparathyroidism
Jaskowiak et al.
Arch Surg 2002;137:659-669.
ABSTRACT
| FULL TEXT
The Influence of Intraoperative Parathyroid Hormone Monitoring on the Surgical Management of Hyperparathyroidism
Mandell et al.
Arch Otolaryngol Head Neck Surg 2001;127:821-827.
ABSTRACT
| FULL TEXT
Relative Contributions of Technetium Tc 99m Sestamibi Scintigraphy, Intraoperative Gamma Probe Detection, and the Rapid Parathyroid Hormone Assay to the Surgical Management of Hyperparathyroidism
Dackiw et al.
Arch Surg 2000;135:550-557.
ABSTRACT
| FULL TEXT
|
